Expert panel boosts precision cancer care in new study

NCT ID NCT05455606

Knowledge-focused Sponsor: SWOG Cancer Research Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach leads to more targeted therapy use and improves doctors' understanding of genetic test results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,284 people

The number who actually took part.

Started

Oct 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * RECRUITMENT CENTERS INCLUSION * A Recruitment Center is defined as an outpatient clinic, or group of clinics, belonging to the same National Cancer Institute Community Oncology Research Program (NCORP) or minority/underserved (MU)-NCORP, who will be contributing physicians and patient participants to the study * Recruitment Centers must be part of an NCORP or MU-NCORP site with Cancer Care Delivery Research (CCDR) funding as this study is supported by CCDR funding. Each clinic included in the Recruitment Center must be associated with Cancer Therapy Evaluation Program (CTEP) site identification (ID). * Recruitment Centers must send large panel next generation sequencing genomic tests on at least 10 unique patients per month. * Recruitment Centers must have at least 4 practicing oncologists (including medical, gynecologic, or neuro-oncologists) at the site willing to participate in the study and register within three months of study activation. * Recruitment Centers must be willing to register a total of 66 patients (over 2 years) to the study. * Centers must be able to send at least one member of the study team to attend the Recruitment Center's cases presented to the S2108CD Genomic Tumor Board, should the Recruitment Center be randomized to the intervention arm. * Recruitment Centers must be willing and able to document the number of unique patients on which GTT is ordered at the Recruitment Center and submit this monthly to the S2108CD Study Team. * PHYSICIAN PARTICIPANT INCLUSION * Physician participant must be a registering investigator of the Recruitment Center that is participating in the study. If the physician is a registering investigator at more than one Recruitment Center, he/she must choose one Recruitment Center to identify with and enroll patients from. * Physician participants must be board-eligible or board-certified in Medical Oncology, Gynecologic Oncology, or Neurology with certification or eligible for certification in Neuro-oncology. * Physician participants must be willing to offer participation in the study to all eligible patients under their care for the duration of the study. A single physician may enroll multiple patients on the study. * Physician participants must be willing to complete all study questionnaires and, as part of the implementation objective, participate in interviews if invited. * Physician participants must complete all baseline questionnaires prior to registration. * Physician participants at a Recruitment Center randomized to the intervention arm must be willing to participate in the educationally enhanced GTB (EGTB). * PATIENT PARTICIPANT INCLUSION * Patient participants must have either recurrent, relapsed, refractory, metastatic, or newly diagnosed advanced stage III or stage IV solid tumor malignancy. * Patient participants must be under the care of a physician enrolled on the study. * Patient participants may have started anti-cancer treatment for the current diagnosis. The treating physician anticipates that the patient will start a new anti-cancer treatment (either first or subsequent lines) within 6 months after registration. * Patient participants are allowed to be co-enrolled on other clinical trials including non-treatment studies and studies that include investigational drugs. Patients may be enrolled on genome-informed therapeutic trials, such as LungMAP, MATCH, TAPUR, etc. * Patient participants' genomic tumor test must have been ordered within 7 days prior to registration with results pending. The genomic testing may be a commercially available panel (such as FoundationOne, Caris, Tempus, etc.) or a non-commercial tumor panel performed at an academic medical center. * NOTE: Qualifying GTTs are defined as Clinical Laboratory Improvement Act (CLIA)-certified next generation sequencing (NGS) tissue or liquid biopsy panels, including hotspot, whole gene, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (including expression data) panels. Fluorescence-in-situ hybridization (FISH) and immunohistochemistry test results assessing cancer-relevant proteins (e.g. Her2/neu, ALK, MET) and immune parameters (e.g. PD-L1 tests) are also permissible if performed in the context of a larger panel that includes NGS or expression profiling. These tests can come from any commercial or academic laboratory within the United States (US) and they should be ordered with the intent to influence genome-informed treatment decision. Oncotype DX and other panels used for making treatment decisions based on a prognostic read-out (e.g. liquid biopsy minimal residual disease \[MRD\]) are not permitted. * Patient participants must be at least 18 years of age. * Patient participants must have a Zubrod performance status of 0-2. * Participants (patients and physicians) must sign and give written informed consent in accordance with institutional and federal guidelines. For patient participants with impaired decision-making capabilities, legally authorized representative may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations. Documentation of informed consent via remote consent is permissible. Exclusion Criteria: * RECRUITMENT CENTERS EXCLUSION * Recruitment Centers must not have or utilize an existing Genomic Tumor Board (GTB). For the purposes of this study, a Genomic Tumor Board is defined as an interdisciplinary team of clinicians and scientists that reviews genomic testing results and provides guidance on treatment options based primarily on genomic data to the treating physician. The existence of a general multidisciplinary tumor board that addresses all aspects of patient care and treatment is not considered an exclusion criterion. A general multidisciplinary tumor board is defined as an interdisciplinary team of clinicians that primarily discusses all aspects of cancer care, including diagnostic aspects (pathology and radiology), therapeutic options (surgical, radiation and medical) as well as palliative and psychosocial support options. * PATIENT PARTICIPANT EXCLUSION * Patient participants must not be going on hospice care at the time of registration.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm Neoplasm Metastasis refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced malignant solid neoplasm Metastatic malignant solid neoplasm Recurrent malignant solid neoplasm Refractory malignant solid neoplasm

Contacts and locations

Locations

Ascension Columbia Saint Mary's Hospital Ozaukee

Mequon, Wisconsin, 53097, United States
Ascension Medical Group Southeast Wisconsin - Mayfair Road

Wauwatosa, Wisconsin, 53226, United States
Ascension Saint Francis - Reiman Cancer Center

Franklin, Wisconsin, 53132, United States
Ascension Saint John Hospital

Detroit, Michigan, 48236, United States
Ascension Southeast Wisconsin Hospital - Elmbrook Campus

Brookfield, Wisconsin, 53045, United States
Cancer Center at Saint Joseph's

Phoenix, Arizona, 85004, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938, United States
Carle at The Riverfront

Danville, Illinois, 61832, United States
Centro Comprensivo de Cancer de UPR

San Juan, 00927, Puerto Rico
CoxHealth South Hospital

Springfield, Missouri, 65807, United States
Delbert Day Cancer Institute at PCRMC

Rolla, Missouri, 65401, United States
Doctors Cancer Center

Manati, 00674, Puerto Rico
Essentia Health Cancer Center

Duluth, Minnesota, 55805, United States
Essentia Health Cancer Center-South University Clinic

Fargo, North Dakota, 58103, United States
Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401, United States
Fairview Lakes Medical Center

Wyoming, Minnesota, 55092, United States
FirstHealth of the Carolinas-Moore Regional Hospital

Pinehurst, North Carolina, 28374, United States
Gibbs Cancer Center-Gaffney

Gaffney, South Carolina, 29341, United States
Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651, United States
Hawaii Cancer Care - Westridge

‘Aiea, Hawaii, 96701, United States
Hawaii Cancer Care Inc - Waterfront Plaza

Honolulu, Hawaii, 96813, United States
HaysMed University of Kansas Health System

Hays, Kansas, 67601, United States
Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704, United States
Illinois CancerCare-Canton

Canton, Illinois, 61520, United States
Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401, United States
Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350, United States
Illinois CancerCare-Peoria

Peoria, Illinois, 61615, United States
Iowa Methodist Medical Center

Des Moines, Iowa, 50309, United States
Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96826, United States
Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854, United States
Lakeview Hospital

Stillwater, Minnesota, 55082, United States
Lawrence Memorial Hospital

Lawrence, Kansas, 66044, United States
Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Savannah, Georgia, 31405, United States
MGC Hematology Oncology-Union

Union, South Carolina, 29379, United States
Medical Oncology and Hematology Associates-Des Moines

Des Moines, Iowa, 50309, United States
Mercy Hospital

Coon Rapids, Minnesota, 55433, United States
Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337, United States
Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125, United States
Missouri Baptist Medical Center

St Louis, Missouri, 63131, United States
Missouri Baptist Outpatient Center-Sunset Hills

Sunset Hills, Missouri, 63127, United States
Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080, United States
New Ulm Medical Center

New Ulm, Minnesota, 56073, United States
Olathe Health Cancer Center

Olathe, Kansas, 66061, United States
Pali Momi Medical Center

‘Aiea, Hawaii, 96701, United States
Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416, United States
Parkland Health Center - Farmington

Farmington, Missouri, 63640, United States
Queen's Medical Center

Honolulu, Hawaii, 96813, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
Ridgeview Medical Center

Waconia, Minnesota, 55387, United States
Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109, United States
Saint Joseph Hospital East

Lexington, Kentucky, 40509, United States
Saint Joseph London

London, Kentucky, 40741, United States
Saint Joseph Mercy Brighton

Brighton, Michigan, 48114, United States
Saint Joseph Mercy Chelsea

Chelsea, Michigan, 48118, United States
Saint Joseph Mercy Hospital

Ann Arbor, Michigan, 48106, United States
Saint Joseph Mercy Oakland

Pontiac, Michigan, 48341, United States
Saint Joseph's/Candler - Bluffton Campus

Bluffton, South Carolina, 29910, United States
Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670, United States
Salina Regional Health Center

Salina, Kansas, 67401, United States
Spartanburg Medical Center

Spartanburg, South Carolina, 29303, United States
Straub Clinic and Hospital

Honolulu, Hawaii, 96813, United States
Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States
Truman Medical Centers

Kansas City, Missouri, 64108, United States
Unity Hospital

Fridley, Minnesota, 55432, United States
University of Hawaii Cancer Center

Honolulu, Hawaii, 96813, United States
University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, Missouri, 64116, United States
University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210, United States
University of Kansas Health System Saint Francis Campus

Topeka, Kansas, 66606, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.